We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.

Bruix, J., Tak, W., Gasbarrini, A., Santoro, A., Colombo, M., Lim, H., Mazzaferro, V., Wiest, R., Reig, M., Wagner, A., Bolondi, L., Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study, <<EUROPEAN JOURNAL OF CANCER>>, 2013; 49 (16): 3412-3419. [doi:10.1016/j.ejca.2013.05.028] [http://hdl.handle.net/10807/52151]

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

Gasbarrini, Antonio;
2013

Abstract

We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.
2013
Inglese
Bruix, J., Tak, W., Gasbarrini, A., Santoro, A., Colombo, M., Lim, H., Mazzaferro, V., Wiest, R., Reig, M., Wagner, A., Bolondi, L., Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study, <<EUROPEAN JOURNAL OF CANCER>>, 2013; 49 (16): 3412-3419. [doi:10.1016/j.ejca.2013.05.028] [http://hdl.handle.net/10807/52151]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/52151
Citazioni
  • ???jsp.display-item.citation.pmc??? 97
  • Scopus 201
  • ???jsp.display-item.citation.isi??? 198
social impact